Former President Donald Trump has announced a 100% tariff on all branded pharmaceutical imports to the United States, effective October 1, 2025, as part of his “America First” trade policy. While generic drugs, which make up roughly 90% of U.S. pharmaceutical sales, are exempt, the tariff directly targets branded and patented medicines, creating immediate concerns for international pharmaceutical companies, including many with operations in Ireland.
Irish-based firms such as Pfizer, Johnson & Johnson, and Regeneron’s European operations are closely monitoring the situation. Companies with manufacturing plants in Ireland that export branded products to the U.S. could face significantly higher costs if they do not establish or expand production facilities in the United States. Some firms, including Roche and Novartis, have already invested in U.S. manufacturing and may qualify for exemptions, but Irish companies without an American presence, or with smaller operations, may need to accelerate plans for U.S. production to maintain competitiveness.
The tariffs are expected to impact global markets. Shares of pharmaceutical companies outside the U.S., particularly those exporting branded drugs from Ireland and other EU countries, have already shown signs of volatility. Analysts warn that without swift adjustments, Irish exports could be delayed, profits squeezed, and jobs linked to the pharma sector threatened.
This move is part of a broader package of import duties, which also includes tariffs of 50% on kitchen cabinets and bathroom vanities, 30% on upholstered furniture, and 25% on heavy trucks. Trump argues that these measures are necessary to reduce the U.S. trade deficit and incentivize domestic manufacturing, but critics highlight the risks for global supply chains and trade relations — concerns that directly touch Ireland’s pharmaceutical industry, one of the country’s largest exporters.
As the October 1 implementation date approaches, Irish pharmaceutical companies are evaluating strategies to comply with the new tariffs, including possible U.S. investment, to ensure continued access to the world’s largest drug market.
